Skip to main content
SpringerLink
Log in

Evidence-based Medicine and Equity: The Exclusion of Disadvantaged Groups

  • Chapter
Evidence-based Practice in Medicine and Health Care

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Biller-Andorno N, Lie R, Ter Meulen R (2002) Evidence based medicine as an instrument for rational health policy. Health Care Analysis 10:261–275

    Article  PubMed  Google Scholar 

  2. Bleyer W, Tejeda H, Murphy S, Brawley O, Smith M, Ungerleider R (1997) Equal participation of minority patients in U.S. national pediatric cancer clinical trials. Journal of Pediatric Hematology Oncology 19: 423–427

    CAS  Google Scholar 

  3. Cookson R, McDaid D, Maynard A (2001) Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? British Medical Journal 323:743–5

    PubMed  CAS  Google Scholar 

  4. Dobson, F (1999) Secretary of State’s speech. http:// www.nice.org.uk/Embcat.asp?page=oldsite/back/frank_dobson.htm&d=907

    Google Scholar 

  5. Dresser R (1992) Wanted, Single white male. Hastings Center Report 22:24–29

    PubMed  CAS  Google Scholar 

  6. Ebrahim S, Smith GD (1997) Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. British Medical Journal 314:1666–1674

    PubMed  CAS  Google Scholar 

  7. Evelyn B, Toigo T, Banks D, Pohl D, Gray K, Robins B, Ernat J (2001) Participation of racial/ethnic groups in clinical trials and race-related labelling: a review of new molecular entities approved 1995-1999. Journal of the National Medical Association 93:18S–24S

    PubMed  CAS  Google Scholar 

  8. European Secondary Prevention Study Group (1996) Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 347: 1203–1207

    Google Scholar 

  9. Giuliano A, Mokuau N, Hughes C, Tortolera-Luna G, Risendal B, Ho R, Prewitt T, McCaskill-Stevens W (2000) Participation of minorities in cancer research: the influence of structural, cultural and linguistic factors. Annals of Epidemiology 10:S22–S34

    Article  PubMed  CAS  Google Scholar 

  10. Global Forum for Health Research (2002) The 10/90 report on health Research. Global Forum for Health Research, Geneva. Cited in: Horton R (2003) Medical journals: evidence of bias against the diseases of poverty. Lancet 361: 712–713

    Google Scholar 

  11. Hanley B, Truesdale A, King A, Elbourne D, Chalmers I (2001) Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. British Medical Journal 322: 519–523

    PubMed  CAS  Google Scholar 

  12. Heiat A, Gross C, Krumholz H (2002) Representation of the elderly, women, and minorities in heart failure clinical trials. Archives of Internal Medicine 162:1682–1688

    Article  PubMed  Google Scholar 

  13. Hooper L, Summerbell C, Higgins J, Thompson R, Capps N, Smith GD, Ebrahim S (2001) Dietary fat intake and prevention of cardiovascular disease: a systematic review. British Medical Journal 322:757–763

    PubMed  CAS  Google Scholar 

  14. Horrobin D (2003) Are large clinical trials in rapidly lethal diseases usually unethical? Lancet 361:695–697

    Article  PubMed  Google Scholar 

  15. Johnson J (2002) Influence of race or ethnicity on pharmacokinetics of drugs. Journal of Pharmaceutical Sciences 86:1328–1333

    Google Scholar 

  16. Kohl H (1995) Physical activity and cardiovascular disease: evidence for a dose response. Medicine and Science in Sports and Exercise 33: S472–S483

    Google Scholar 

  17. Matthews H (1995) Racial, ethnic and gender differences in response to medicines. Drug Metabolism & Drug Interactions 12:77–91

    CAS  Google Scholar 

  18. McAlister F, Taylor L, Teo K, Tsuyuki R, Ackman M, Yim R, Montague T (1999) The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? Journal of the American Geriatrics Society 47:811–818

    PubMed  CAS  Google Scholar 

  19. Miller B, Koloel L, Bernstein L, Young J, Swanson G, West D, et al. (1996) Racial/ethnic patterns of cancer in the United States 1988-92. Bethesda, MD: National Cancer Institute, Bethesda. Cited in: Giuliano A et al. (2000) Participation of minorities in cancer research: the influence of structural, cultural and linguistic factors. Annals of Epidemiology 10: S22-S34

    Google Scholar 

  20. Moye LA, Powell JH (2001) Evaluation of ethnic minorities and gender effects in clinical trials: opportunities lost and rediscovered. Journal of the National Medical Association 93:29S–34S

    PubMed  CAS  Google Scholar 

  21. Norheim OF (2002) The role of evidence in health policy making: a normative perspective. Health Care Analysis 10:309–317

    Article  PubMed  Google Scholar 

  22. Owen W, Szczech L, Frankenfield D (2002) Health-care system interventions for inequality in quality: corrective action through Evidence-based Medicine. Journal of the National Medical Association 94:83S–91S

    PubMed  Google Scholar 

  23. Raferty J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. British Medical Journal 323: 1300–1303

    Google Scholar 

  24. Rochon P, Clark J, Binns M, Patel V, Gurwitz J (1998) Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. Canadian Medical Association Journal 159:321–327

    PubMed  CAS  Google Scholar 

  25. Rogers WA (2002) Evidence-based Medicine in practice: Limiting or facilitating patient choice? Health Expectations 5:95–103

    Article  PubMed  Google Scholar 

  26. Sateren W, Trimble E, Brawley O, Breen N, Ford L, McCabe M, Ungerleider R, Christian M (2002) How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. Journal of Clinical Oncology 20:2109–2117

    Article  PubMed  Google Scholar 

  27. Sherr L (2000) Women and clinical trials. In: Sherr L, St Lawrence J (Eds.) Women, health and the mind. John Wiley and Sons, Chichester, P 47–58

    Google Scholar 

  28. Starfield B (2001) New paradigms for quality in primary care. British Journal of General Practice 51:303–309

    PubMed  CAS  Google Scholar 

  29. Sterne J, Egge M, Smith GD (2001) Investigating and dealing with publication and other biases in meta-analysis. British Medical Journal 323:101–105

    PubMed  CAS  Google Scholar 

  30. Swanson GM, Bailar JC (2002) Selection and description of cancer clinical trials participants — science or happenstance? Cancer 95:950–959

    Article  PubMed  Google Scholar 

  31. Taylor AL (2001) SERMs, ethnicity, and clinical trials: opportunities and challenges. Annals of the New York Academy of Sciences 949: 292–294

    PubMed  CAS  Google Scholar 

  32. Watt G (2002) The inverse care law today. Lancet 360: 252–4

    Article  PubMed  Google Scholar 

  33. Weissman N (2000) Relation of race and sex to the use of reperfusion therapy in Medicare beneficiaries with acute myocardial infarction. New England Journal of Medicine 324:1094–1100

    Google Scholar 

  34. World Health Organisation (2002) The World Health Report 2002. World Health Organisation, Geneva

    Google Scholar 

Download references

Authors
  1. Wendy A. Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Instituut voor Gezondheidsethiek, Universiteit Maastricht, Universiteitssingel 40 (West), NL-6229, ER Maastricht, Germany

    Ruud ter Meulen

  2. Professur f. Medizinethik, Charité — Universitätsmedizin Berlin, Klingsorstrasse 119, D-12203, Berlin, Germany

    Nikola Biller-Andorno

  3. Abt. Ethik und Geschichte der Medizin, Universität Göttingen, Humboldtallee 36, D-37073, Goettingen, Germany

    Christian Lenk

  4. Department of Clinical Bioethics, National Institutes of Health, 10 Center Drive Building 10, Room 1C118, Bethesda, MD, 20892-1156, USA

    Reidar K. Lie MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rogers, W.A. (2005). Evidence-based Medicine and Equity: The Exclusion of Disadvantaged Groups. In: ter Meulen, R., Biller-Andorno, N., Lenk, C., Lie, R.K. (eds) Evidence-based Practice in Medicine and Health Care. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27133-3_14

Download citation

  • DOI: https://doi.org/10.1007/3-540-27133-3_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22239-2

  • Online ISBN: 978-3-540-27133-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation